At Aerami Therapeutics, we leverage our proprietary inhalation technology to develop differentiated inhaled therapies for the treatment of severe respiratory and other chronic diseases.
A drug-device combination product candidate in Phase 1 for the treatment of pulmonary arterial hypertension
A soft mist inhaled human insulin for the treatment of Type 1 and 2 diabetes
An inhaled glucagon-like peptide-1 (GLP-1) analog for Type 2 diabetes
Aerami Therapeutics is a clinical stage biopharmaceutical company engaged in the development of differentiated inhaled therapies for the treatment of severe respiratory and other chronic diseases.
Sign up today and receive company updates straight to your inbox.